Tech Company Financing Transactions
CoRegen Funding Round
CoRegen secured a $93 million funding round on 7/9/2025. Backers included private investors.
Transaction Overview
Company Name
Announced On
7/9/2025
Transaction Type
Venture Equity
Amount
$93,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance its chemistry, manufacturing, and controls (CMC) development, initiate a Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) program in patients with various solid-tumor types in the first half of 2026 and expand its leadership team with key hires to drive execution and support its growth.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Houston, TX 77030
USA
Houston, TX 77030
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Advancing life-changing therapies with innovation and purpose. Our mission is to pioneer next-generation treatments that eliminate a wide range of chronic illnesses and redefine what's possible in modern medicine. Through relentless research, cutting-edge biotechnology, and an unwavering commitment to patients, we are reshaping the future of healthcare. CoRegen is founded on these key principles.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Suneet Varma
Browse more venture capital transactions:
Prev: 7/9/2025: MaintainX venture capital transaction
Next: 7/9/2025: Neuros Medical venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs